Jane Street Group LLC Sells 58,870 Shares of Progyny, Inc. (NASDAQ:PGNY)

Jane Street Group LLC cut its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 43.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 76,660 shares of the company's stock after selling 58,870 shares during the quarter. Jane Street Group LLC owned 0.09% of Progyny worth $1,322,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of PGNY. Barclays PLC increased its stake in Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after buying an additional 594,140 shares during the period. Franklin Resources Inc. boosted its position in Progyny by 17.0% during the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company's stock valued at $759,000 after purchasing an additional 7,003 shares during the last quarter. Ballentine Partners LLC purchased a new position in Progyny in the fourth quarter valued at about $187,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Progyny during the 4th quarter worth about $989,000. Finally, Fort Washington Investment Advisors Inc. OH grew its stake in shares of Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after buying an additional 695,740 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Wall Street Analysts Forecast Growth

PGNY has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a report on Monday, March 31st. Bank of America upped their target price on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group dropped their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $23.45.

Progyny Price Performance

PGNY stock traded down $0.37 on Friday, reaching $20.52. 822,500 shares of the company were exchanged, compared to its average volume of 1,712,711. The firm has a market capitalization of $1.76 billion, a PE ratio of 35.38, a PEG ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $30.42. The stock's fifty day moving average price is $22.15 and its 200 day moving average price is $19.98.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The company had revenue of $324.04 million during the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 earnings per share. As a group, research analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.